Ajanta Pharma Limited (AJANTPHARM) Fair Value & Analysis
Healthcare · IN · Market cap ₹433B (≈ $4.6B) · ISIN INE031B01049
What is Ajanta Pharma Limited really worth?
A solid business, but trading 164% above our fair value of ₹1,312.
As of Aug 30, 2026, the fair value of Ajanta Pharma Limited is ₹1,312 per share against a price of ₹3,464, so the fair value sits 62% below the price. A model estimate blended from multiple valuation models, recalculated regularly.
Strengths
Risks
For context
Fair value as of: Aug 30, 2026
From 24 valuation models · updated 7 days ago
Share price −0.2% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (₹2,222). The favourable scenario is already priced in.
- The model range is unusually wide (₹754.37 to ₹2,222). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- Solid but not exceptional quality (64/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 30, 2026.
How to read this chart
60‑month range ₹1,058 – ₹3,713 · fair‑value band ₹754.37 – ₹2,222 · the ₹3,464 price screens above the ₹1,312 fair value. Dashed = 300-day average. As of Aug 30, 2026.
Analysis
Ajanta Pharma Limited (AJANTPHARM) currently trades at ₹3,464, while our model-based Fair Value estimate is ₹1,312, implying the stock looks roughly 164.0% overvalued today. The Quality Score stands at 64/100 (solid quality), in the Healthcare sector. Bull case: the Growth Earnings group reads highest at a median of ₹1,709 per share, and 0 of the 24 models we run sit above the ₹3,464 price. Bear case: the Asset-Based group reads lowest at ₹242.78, and 24 of the 24 models stay below the price. Evidence for this calculation is high.
Over the trailing twelve months, Ajanta Pharma Limited generated revenue of ₹52.0B at a net margin of 19.5%. Revenue grew 20.0% year over year. It earns a return on equity of 24.4%. Net debt stands at ₹1.1B. Fundamentals as of Aug 30, 2026
Our scenario range runs from ₹754.37 (bear case) to ₹2,222 (bull case); at ₹3,464, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 4% below its 52-week high and 50% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −62%, AJANTPHARM screens richer than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly ₹36.23 per share, which is 2.6 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 24 models by family
Widest divergence: Growth Earnings (₹1,709) versus Asset-Based (₹242.78). Highest evidence: FCF DCF (76).
Notify me when AJANTPHARM reaches fair value
Put AJANTPHARM on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 30, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 61 · Market factors (momentum, volatility) 79
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets speciality pharmaceutical finished dosages. The company markets and serves various therapeutic segments, such as cardiology, antidiabetic, ophthalmology, dermatology, pain management, and respiratory areas.
Full company description
Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets speciality pharmaceutical finished dosages. The company markets and serves various therapeutic segments, such as cardiology, antidiabetic, ophthalmology, dermatology, pain management, and respiratory areas. It also provides tablets, capsules, injectables, inhalers, ointments, creams, and liquids. The company serves in India, Africa, rest of Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Ajanta Pharma Limited reported revenue of ₹54.1B in FY2025 versus ₹33.4B in FY2021, a compound +12.8%/yr. Reported net income was ₹10.6B in FY2025, compounding +10.3%/yr from FY2021.
AJANTPHARM screens 164% overvalued. Compare with Merck KGaA →
Peer Group
Drug Manufacturers - Specialty & Generic · 609 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 30, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Merck KGaA MRK | €140.25 | €106.48 | −24% |
| Takeda Pharmaceutical Company TAK | $18.03 | $11.11 | −38% |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.76 | ¥25.94 | −52% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,899 | ₹989.50 | −48% |
| Galderma Group GALD | CHF 178.55 | CHF 55.07 | −69% |
| Haleon plc HLN | $10.11 | $7.64 | −24% |
| Teva Pharmaceutical Industries Limited TEVA | $36.05 | $15.33 | −57% |
| Sandoz Group SDZ | CHF 70.66 | CHF 39.21 | −45% |
| Zoetis Inc ZTS | $77.10 | $104.88 | +36% |
| Hansoh Pharmaceutical Group 3692 | HK$35.12 | HK$16.18 | −54% |
Compare Ajanta Pharma Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Ajanta Pharma Limited (AJANTPHARM) overvalued or undervalued?
What is the fair value of AJANTPHARM?
What is the quality score of AJANTPHARM?
What is the price target for Ajanta Pharma Limited (AJANTPHARM)?
What is the Ajanta Pharma Limited stock forecast for 2026?
What is the revenue of Ajanta Pharma Limited (AJANTPHARM)?
What is the net profit margin of AJANTPHARM?
Does Ajanta Pharma Limited pay a dividend?
Watch Ajanta Pharma Limited in the live analysis
One click puts Ajanta Pharma Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.